Original Research PaperPreparation and evaluation of Duloxetine hydrochloride (cas 136434-34-9) enteric-coated pellets with different enteric polymers
-
Add time:09/03/2019 Source:sciencedirect.com
The main purpose of the present study was to prepare Duloxetine hydrochloride (cas 136434-34-9) (DXH) enteric-coated pellets using different enteric polymers. Three layers (drug-loaded layer, barrier layer, and enteric-coated layer) were applied to the inert core pellets, successively. The optimal formulation was manufactured by employing suspension layering method in fluidized bed processor (FBP) with varieties of enteric polymers like Aqoat® AS-LF, Eudragit® L30D55 and HPMCP-HP55. The prepared pellets were measured for physical characterization and the in vitro dissolution profile. Scanning electron microscopy (SEM) was conducted to observe the morphology of pellets, and different kinetic models were applied to analyze the release mechanism of Cymbalta® and home-made pellets. The coating weight gain of enteric-coated layer containing Eudragit® L30D55, Aqoat® AS-LF and HP-55 were determined to be 35%, 26% and 24%, respectively. The similarity factors (f2) of self-made capsules with above polymers and commercially available capsules (Cymbalta®) were above 50 in the dissolution medium of pH 6.8 phosphate buffer solution (PBS). SEM figures showed the smooth surfaces of self-prepared pellets using Eudragit® L30D55 and Aqoat® AS-LF, whereas rough surface was found in the HP-55 pellets at day 0, and an impurity was appearing in the condition of 40 °C/75% relative humidity for 1 month. In conclusion, the pellets prepared by utilizing Eudragit® L30D55 and Aqoat® AS-LF were the optimal preparations based on the dissolution profile and stability.
We also recommend Trading Suppliers and Manufacturers of Duloxetine hydrochloride (cas 136434-34-9). Pls Click Website Link as below: cas 136434-34-9 suppliers
Prev:Development and validation of an analytical method for the stability of Duloxetine hydrochloride (cas 136434-34-9)
Next:Study on fluorescence characteristics of Duloxetine hydrochloride (cas 136434-34-9)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ArticleA rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study09/08/2019
- Artifactual formylation of the secondary amine of Duloxetine hydrochloride (cas 136434-34-9) by acetonitrile in the presence of titanium dioxide: Implications for HPLC method development09/07/2019
- Original articleCase Report: Fulminant Hepatic Failure Involving Duloxetine hydrochloride (cas 136434-34-9)09/06/2019
- Original articleStudy on the binding of chiral drug Duloxetine hydrochloride (cas 136434-34-9) to human serum albumin☆09/05/2019
- Study on fluorescence characteristics of Duloxetine hydrochloride (cas 136434-34-9)09/04/2019
- Development and validation of an analytical method for the stability of Duloxetine hydrochloride (cas 136434-34-9)09/02/2019
- Optimization and in vivo evaluation of Duloxetine hydrochloride (cas 136434-34-9) buccoadhesive lyophilized tablets09/01/2019
-
Health and Chemical more >


